Target cell-specific synaptic dynamics of excitatory to inhibitory neuron connections in supragranular layers of human neocortex

Rodent studies have demonstrated that synaptic dynamics from excitatory to inhibitory neuron types are often dependent on the target cell type. However, these target cell-specific properties have not been well investigated in human cortex, where there are major technical challenges in reliably obtaining healthy tissue, conducting multiple patch-clamp recordings on inhibitory cell types, and identifying those cell types. Here, we take advantage of newly developed methods for human neurosurgical tissue analysis with multiple patch-clamp recordings, post-hoc fluorescent in situ hybridization (FISH), machine learning-based cell type classification and prospective GABAergic AAV-based labeling to investigate synaptic properties between pyramidal neurons and PVALB- vs. SST-positive interneurons. We find that there are robust molecular differences in synapse-associated genes between these neuron types, and that individual presynaptic pyramidal neurons evoke postsynaptic responses with heterogeneous synaptic dynamics in different postsynaptic cell types. Using molecular identification with FISH and classifiers based on transcriptomically identified PVALB neurons analyzed by Patch-seq, we find that PVALB neurons typically show depressing synaptic characteristics, whereas other interneuron types including SST-positive neurons show facilitating characteristics. Together, these data support the existence of target cell-specific synaptic properties in human cortex that are similar to rodent, thereby indicating evolutionary conservation of local circuit connectivity motifs from excitatory to inhibitory neurons and their synaptic dynamics.

For all that apply, please note where in the article the information is provided. Please note that we also collect information about data availability and ethics in the submission form.

Materials:
Newly created materials Indicate where provided: section/figure legend

N/A
The manuscript includes a dedicated "materials availability statement" providing transparent disclosure about availability of newly created materials including details on how materials can be accessed and describing any restrictions on access.
There are no newly created materials in this study. Design:

Antibodies
Study protocol Indicate where provided: If the study protocol has been pre-registered, provide DOI. For clinical trials, provide the trial registration number OR cite DOI.
The study protocol is described in the Methods section, but nothing is preregistered.
Laboratory protocol Indicate where provided: Provide DOI OR other citation details if detailed step-by-step protocols are available.
Synaptic physiology experimental protocol is also described in https://portal.brainmap.org/explore/conn ectivity/synapticphysiology and it is described in Methods section, Data availability. Data availability Indicate where provided: section/submission form

N/A
For newly created and reused datasets, the manuscript includes a data availability statement that provides details for access (or notes restrictions on access).
It is described in the section of Methods, Data availability.
When newly created datasets are publicly available, provide accession number in repository OR DOI and licensing details where available.
It is described in the section of Methods, Data availability.
If reused data is publicly available provide accession number in repository OR DOI, OR URL, OR citation.
It is described in the section of Methods, Data availability.
Code availability Indicate where provided: section/figure legend

N/A
For any computer code/software/mathematical algorithms essential for replicating the main findings of the study, whether newly generated or re-used, the manuscript includes a data availability statement that provides details for access or notes restrictions.
It is described in the section of Methods, Data availability.
Where newly generated code is publicly available, provide accession number in repository, OR DOI OR URL and licensing details where available. State any restrictions on code availability or accessibility.
It is described in the section of Methods, Data availability.
If reused code is publicly available provide accession number in repository OR DOI OR URL, OR citation.
It is described in the Methods section such as IPFX python package and QuPath software.

Reporting:
The MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives.
Adherence to community standards Indicate where provided: State if relevant guidelines (e.g., ICMJE, MIBBI, ARRIVE, STRANGE) have been followed, and whether a checklist (e.g., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.
No relevant guidelines have been followed. Only NDAR checklist has been provided with the manuscript.
* We provide the following guidance regarding transparent reporting and statistics; we also refer authors to Ten common statistical mistakes to watch out for when writing or reviewing a manuscript.
Sample-size estimation • You should state whether an appropriate sample size was computed when the study was being designed • You should state the statistical method of sample size computation and any required assumptions • If no explicit power analysis was used, you should describe how you decided what sample (replicate) size (number) to use

Replicates
• You should report how often each experiment was performed • You should include a definition of biological versus technical replication • The data obtained should be provided and sufficient information should be provided to indicate the number of independent biological and/or technical replicates • If you encountered any outliers, you should describe how these were handled • Criteria for exclusion/inclusion of data should be clearly stated • High-throughput sequence data should be uploaded before submission, with a private link for reviewers provided (these are available from both GEO and ArrayExpress) Statistical reporting • Statistical analysis methods should be described and justified • Raw data should be presented in figures whenever informative to do so (typically when N per group is less than 10) • For each experiment, you should identify the statistical tests used, exact values of N, definitions of center, methods of multiple test correction, and dispersion and precision measures (e.g., mean, median, SD, SEM, confidence intervals; and, for the major substantive results, a measure of effect